REACTIVATION OF ERK AND AKT CONFERS RESISTANCE OF MUTANT BRAF COLON CANCER CELLS TO THE HSP90 INHIBITOR AUY922

被引：0
|
作者：
Wang, Chun Yan [1 ,2 ]
Guo, Su Tang [1 ,2 ]
Wang, Jia Yu [1 ]
Yan, Xu Guang [1 ]
Farrelly, Margaret [1 ]
Zhang, Yuan Yuan [3 ]
Liu, Fen [1 ]
Yari, Hamed [1 ]
La, Ting [1 ]
Lei, Fu Xi [1 ]
Jin, Lei [3 ]
Zhang, Xu Dong [1 ]
Jiang, Chen Chen [3 ]
机构：
[1] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia
[2] Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan, Shanxi, Peoples R China
[3] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P55
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [1] Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922
    Wang, Chun Yan
    Guo, Su Tang
    Wang, Jia Yu
    Yan, Xu Guang
    Farrelly, Margaret
    Zhang, Yuan Yuan
    Liu, Fen
    Yari, Hamed
    La, Ting
    Lei, Fu Xi
    Jin, Lei
    Zhang, Xu Dong
    Jiang, Chen Chen
    ONCOTARGET, 2016, 7 (31) : 49597 - 49610
  • [2] BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922
    Wang, Chun Yan
    Guo, Su Tang
    Croft, Amanda
    Yan, Xu Guang
    Jin, Lei
    Zhang, Xu Dong
    Jiang, Chen Chen
    MOLECULAR CARCINOGENESIS, 2018, 57 (02) : 284 - 294
  • [3] Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress
    Wang, Chun Yan
    Guo, Su Tang
    Wang, Jia Yu
    Liu, Fen
    Zhang, Yuan Yuan
    Yari, Hamed
    Yan, Xu Guang
    Jin, Lei
    Zhang, Xu Dong
    Jiang, Chen Chen
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (03) : 448 - 459
  • [4] Inhibition of hsp90 by auy922 preferentially kills mutant KRAS colon cancer cells by activating Bim through ER stress
    Wang, Chun Yan
    Guo, Su Tang
    Wang, Jia Yu
    Yan, Xu Guang
    Farrelly, Margaret
    Zhang, Yuan Yuan
    Liu, Fen
    Yari, Hamed
    La, Ting
    Lei, Fu Xi
    Jin, Lei
    Jiang, Chen Chen
    Zhang, Xu Dong
    CANCER RESEARCH, 2017, 77
  • [5] Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma
    Kosovec, Juliann E.
    Zaidi, Ali H.
    Kelly, Lori A.
    Rotoloni, Christina L.
    Vytlacil, Christopher
    DiCarlo, Christina
    Matsui, Daisuke
    Komatsu, Yoshihiro
    Boyd, Natalie H.
    Omstead, Ashten
    Kolano, Elena L.
    Biederman, Robert W. W.
    Finley, Gene
    Silverman, Jan F.
    Landreneau, Rodney J.
    Jobe, Blair A.
    ANNALS OF SURGERY, 2016, 264 (02) : 297 - 304
  • [6] Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
    Cheng, Wei
    Ainiwaer, Aimudula
    Xiao, Lei
    Cao, Qian
    Wu, Ge
    Yang, Ying
    Mao, Rui
    Bao, Yongxing
    MOLECULAR MEDICINE REPORTS, 2015, 12 (02) : 2451 - 2456
  • [7] HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells
    Bai, Jingchao
    Zhou, Guanglin
    Qiu, Yufan
    Hu, Yunhui
    Liu, Jingjing
    Zhao, Jing
    Zhang, Sheng
    Zhang, Jin
    CANCER SCIENCE, 2017, 108 (06) : 1177 - 1184
  • [8] A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
    D. J. Renouf
    D. Hedley
    M. K. Krzyzanowska
    M. Schmuck
    L. Wang
    M. J. Moore
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 541 - 545
  • [9] A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
    Renouf, D. J.
    Hedley, D.
    Krzyzanowska, M. K.
    Schmuck, M.
    Wang, L.
    Moore, M. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 541 - 545
  • [10] Anticancer activity of Hsp90 inhibitor AUY922 in nasopharyngeal carcinoma and non-small cell lung cancer cells
    Cho, William C.
    Wong, Chi F.
    CANCER RESEARCH, 2023, 83 (07)
12345